Northwest Medical Isotopes

Northwest Medical Isotopes, LLC (NWMI) was founded with the mission to design, license, construct, and operate facilities for the production of Molybdenum-99 (Mo-99), a critical radioisotope used in nuclear medicine. The company focuses on sustainable technologies to support the entire Mo-99 production process, including target fabrication, recovery, purification from irradiated low-enriched uranium (LEU) targets, and uranium recovery and recycling. NWMI aims to address the significant demand for Mo-99 in the U.S. healthcare market.

Notable affiliates and investors include experts in nuclear medicine and radiopharmaceuticals, though specific names are not provided. Key achievements include advancing the design and licensing processes for their production facilities, contributing to the domestic supply of Mo-99, and enhancing the sustainability of radiopharmaceutical production. NWMI's impact lies in its potential to significantly reduce the U.S. reliance on foreign sources of Mo-99, ensuring a stable and reliable supply for medical diagnostics and treatments.